GLP-1s

Genetics and genomics represent a huge opportunity for health systems, but they also bring considerable challenges related to patient access, physician workloads and precision medicine program implementation. 

Optum is tracking four drugs for recent or potential mid-2021 FDA approval, according to the payer's latest Drug Pipeline Insights Report.

Medicare members could face barriers to accessing Biogen's new Alzheimer's drug, Aduhelm, due to the treatment's high cost.

With Biogen gaining FDA approval for its Alzheimer's drug, aducanumab, questions have started to swirl around how health insurers will cover the $56,000-a-year treatment.

Two members of the Sackler family, which owned Purdue Pharma, will testify Dec. 17 before the U.S. House Committee on Oversight and Reform.

Many public health experts have said the pandemic has exacerbated the opioid epidemic, as social isolation, moving recovery programs to remote settings and stress have led to an increase in opioid abuse and overdoses.

The COVID-19 pandemic has drastically altered health systems’ priorities, leading to the redistribution and reallocation of human and financial resources towards pandemic-related prevention and treatment efforts. During this time, a parallel public health emergency — the national epidemic of opioid-related…

Medicaid spending on opioid overdose-reversal drug naloxone shot up from $110,000 in 2010 to close to $15 million in 2018, according to a study released Aug. 26 by Washington, D.C. think tank the Urban Institute.

UnitedHealthcare is changing which medication for HIV prevention it considers a covered option for members.

Even though opioid overdoses reached their all-time peak in 2019, opioid prescriptions decreased by 37.1 percent from 2014-19, according to the most recent report from the American Medical Association's Opioid Task Force.